German Blockchain & AI Week 2025: Agenda BEAM ‘Bridging European and Asian Markets’
BERLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Berlin, Europe's blockchain capital, is…
AgEagle Aerial Systems Featured at European UAS Conference XPONENTIAL Showcasing Leading Autonomous Technologies and Robotics
AgEagle’s entire product on display through industry-leading defense partners WICHITA, Kan., Feb.…
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE, XBRYK)
OBODENCE™ and XBRYK™ approved by the European Commission (EC) for all indications…
Coffee Island brings India’s first European Coffee Culture with its launch in Gurugram
Opens its first store in India at HQ27 Gurugram in partnership with…
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohns and Colitis Organization 20th Annual Congress
January 23, 2025 16:05 ET | Source: Abivax Abivax Announces Presentation of…
Illuccix Receives European Approval
January 16, 2025 17:06 ET | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia…
Stmm’s Continuous Bioreactor Increases Antibody Productivity by up to 30x in European and American Pilots
Pilot runs in Europe and South America show breakthrough efficiency in monoclonal…
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://i3.wp.com/mma.prnewswire.com/media/597589/4648918/Norgine_Logo.jpg?p=thumbnail&w=420&resize=420,280&ssl=1 "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma"){kind=logo}
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ --…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…